Hepatitis C - SCYNEXIS Announces New Board Chairman and New Board Member

SCYNEXIS Announces New Board Chairman and New Board Member
dBusinessNews.com - Triangle - RESEARCH TRIANGLE PARK -- SCYNEXIS, Inc., a chemistry-focused drug discovery and development company, today announced that Dr. Pamela Kirby has been selected as the new Chairman of the Company's Board of Directors replacing Mr. Philip

BHIVA: HIV/HCV coinfected may have worse survival as they spend less
Aidsmap - HIV-positive individuals who are coinfected with the hepatitis C virus appear to have slightly worse survival than patients who are only infected with HIV, according to data from a study involving HIV-positive patients taking antiretroviral

Relative Risks Of Cirrhosis From Non-alcoholic Steatohepatitis
Medical News Today - Cirrhosis related to non-alcoholic steatohepatitis (NASH) is associated with fewer complications and a lower mortality compared to cirrhosis from hepatitis C, despite NASH patients' greater risk of dying from cardiovascular events. These findings are

Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to

Activists: Hepatitis C clinical trial unfairly excludes blacks
Advocate - Two advocacy groups are blasting the decision by pharmaceutical company Schering-Plough to exclude African-Americans from a clinical trial of its experimental hepatitis C treatment, a decision the company says was needed to better gauge the efficacy

Tata may make Rs 1 lakh car in Jamshedpur
Financial Express - JAMSHEDPUR, MARCH 28: Tata Motors may choose to produce its Rs 1 lakh car in Jamshedpur. It is at a preliminary stage. They have their expansion plan for Jamshedpur. We are discussing that (Rs 1 lakh car project), said a senior bureaucrat from

Novartis Seen 'Saving Face' With Idenix Hep C Deal
Forbes - Friedman, Billings, Ramsey reiterated an "outperform" rating on Idenix Pharmaceuticals after Swiss pharmaceutical titan Novartis exercised an option to co-develop the biotech firm's lead drug candidate. Novartis (nyse: NVS - news - people ) will pay